Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292

ASTRAZENECA PLC

(AZN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : India tells overseas vaccine buyers it has to prioritise local needs

03/26/2021 | 11:29am EDT
The spread of the coronavirus disease (COVID-19), in Mumbai

NEW DELHI (Reuters) - India, the world's biggest vaccine maker, said on Friday it would make domestic COVID-19 inoculations a priority as infections surge and had told international buyers of its decision.

Reports that India will delay deliveries of AstraZeneca's COVID-19 vaccine to a global programme to inoculate poorer countries triggered alarm on Thursday, with the head of Africa's disease control agency describing the continent as "helpless".

India has exported 60.5 million doses, more than the number of inoculations conducted at home, and says there is no outright ban on exports.

"In the coming weeks and months ... obviously there will be a demand spike and obviously people are preparing for it," Subrahmanyam Jaishankar, the minister of external affairs, told the Times Network's India Economic Enclave.

"In many cases, we have told our international partners that ... COVID rates are going up in India, we are expanding our own vaccination ambit, so we are sure you will understand that at this time we have to purpose it much more focused at where we are."

The Gavi alliance said in a statement that the COVAX vaccine-sharing facility had notified all affected economies of potential delays of exports by the Serum Institute of India (SII).

India is diverting more supplies from SII to inoculations at home. Its other vaccine maker, Bharat Biotech, is struggling to boost output.

"SII has pledged that, alongside supplying India, it will prioritize the COVAX multilateral solution for equitable distribution," Gavi said.

COVAX is a global vaccine allocation plan co-led by the World Health Organization and partners including the Gavi alliance.

India on Friday reported 59,118 new infections, taking its tally to 11.85 million. The death toll rose by 257 to stand at 160,949.

Everyone above 45 in India is eligible for vaccination from April 1 and the government is considering including more people after new infections nearly quadrupled this month.

"The government is already planning to widen the umbrella of COVID-19 vaccine beneficiaries in the near future to cover other sections of our population," Health Minister Harsh Vardhan told a virtual summit organised by the Economic Times newspaper.

India has injected 55 million vaccine doses, the third highest figure after the United States and Brazil, although much lower as a proportion of its population of 1.35 billion, the website Our World in Data showed.

The western state of Maharashtra, hardest hit by a resurgence in cases, has warned of vaccine shortages and imposed lockdowns in some towns.

Maharashtra Chief Minister Uddhav Thackeray said the state government would impose a night curfew from Sunday to stem the spread of the coronavirus, and authorities could also impose local lockdowns in some districts after informing people in advance. In another measure, the state will shut shopping malls from 7 p.m. until 6 a.m. local time.

Thackeray said although his government has beefed up health-care facilities, rising coronavirus cases could overwhelm hospitals.

Maharashtra's Pune district on Thursday reported a record 6,427 new cases, the highest in the country.

"If the current surge in coronavirus cases remains there for the next few days, there will be no option but to impose a strict lockdown in Pune from April 2," Maharashtra's deputy chief minister, Ajit Pawar, told a news conference.

Separately, a fire in one hospital near Mumbai killed at least nine coronavirus patients.

(Global vaccination tracker: https://graphics.reuters.com/world-coronavirus-tracker-and-maps/vaccination-rollout-and-access)

(Interactive graphic tracking global spread of coronavirus: https://graphics.reuters.com/world-coronavirus-tracker-and-maps)

(Reporting by Neha Arora; Additional reporting by Shilpa Jamkhandikar and Mayank Bhardwaj; Editing by Krishna N. Das, Nick Macfie and Jonathan Oatis)

By Neha Arora and Rajendra Jadhav


ę Reuters 2021
All news about ASTRAZENECA PLC
08:38aASTRAZENECA : Japan to ship total of 1.6 mil. COVID vaccine doses to Nepal
AQ
03:10aThai hospital tycoon who promised Pfizer vaccine says deal now unlikely
RE
08/03ASTRAZENECA : Chilean study shows variations in success of COVID-19 vaccines
RE
08/03THE LATEST : NYC: Vaccination proof for indoor dining, gyms
AQ
08/03ASTRAZENECA : SAPHNELO approved in the US for moderate to severe systemic lupus ..
AQ
08/03ASTRAZENECA : Sanwo-Olu - Lagos Recorded 4,300 Cases, 30 Fatalities in July
AQ
08/03ASTRAZENECA : Covid-19 Third Wave - Lagos Records 42 Deaths in One Week - Sanwo-..
AQ
08/02Fancy a Covid jab? Here are all the free walk-in sites open in London
AQ
08/02U.S. Food and Drug Administration Approves AstraZeneca PLC's SaphneloÖ (Anifr..
CI
08/02SAPHNELO (Anifrolumab) Approved in the US for Moderate to Severe Systemic Lup..
CI
More news
Financials (USD)
Sales 2021 35 065 M - -
Net income 2021 5 236 M - -
Net Debt 2021 25 946 M - -
P/E ratio 2021 30,5x
Yield 2021 2,44%
Capitalization 179 B 179 B -
EV / Sales 2021 5,84x
EV / Sales 2022 4,76x
Nbr of Employees 76 100
Free-Float 96,4%
Chart ASTRAZENECA PLC
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Last Close Price 115,47 $
Average target price 133,83 $
Spread / Average Target 15,9%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capi. (M$)
ASTRAZENECA PLC13.29%178 598
JOHNSON & JOHNSON10.81%459 079
ROCHE HOLDING AG14.16%340 492
PFIZER, INC.24.10%255 703
ELI LILLY AND COMPANY51.62%232 701
NOVARTIS AG-0.20%224 638